Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression
British Journal of Haematology · 2025-06 · 206 (6) · 1615-1626
DOI: 10.1111/bjh.20106 ↗Kurz gefasst
Fachartikel in der Zeitschrift British Journal of Haematology, online erschienen am 22.04.2025. Verfasst von Wataru Kuroki und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan. Hauptthemen laut MEDLINE: Multiple Myeloma, ADP-ribosyl Cyclase 1, Receptors, Interleukin-6, Chromosomes, Human, Pair 1. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 56 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science, Japanese Society of Myeloma Research Award.
Abstract (Originalsprache)
Multiple myeloma (MM) with chromosome 1q21 gain/amplification (1q+) has been reported to respond poorly to daratumumab. We aimed to explore the mechanism of daratumumab resistance in 1q+ MM. Our findings revealed significantly lower CD38 expression in patients with 1q+ MM than in those with 1q wild type (WT) MM. Next, we focused on the interleukin‐6 receptor (IL6R) located in the 1q21 region because a previous report shows that interleukin‐6 (IL‐6) reduces CD38 expression via the IL‐6/Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway activation in MM. Indeed, IL6R expression was significantly higher in 1q+ MM than in 1q WT MM. We verified that the 1q+ human myeloma cell lines (HMCLs) expressed higher IL6R levels than the 1q WT HMCLs. IL‐6 treatment induced CD38 downregulation in both the 1q+ HMCLs and primary bone marrow (BM) samples but not in their 1q WT HMCLs and BM samples. IL‐6 also resulted in the upregulation of phosphorylated STAT3 in 1q+ HMCLs but not in the 1q WT HMCLs. Furthermore, inhibition of the IL‐6/JAK/STAT pathway by treatment with ruxolitinib or tocilizumab restored CD38 expression in the 1q+ HMCLs and BM samples. These findings elucidate the mechanisms underlying daratumumab resistance in 1q+ MM and provide insights for future therapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Hematology, Nephrology and Rheumatology, Akita University Graduate School of Medicine, Akita, Japan.
- Department of Life Science, Graduate School of Engineering Science, Akita University, Akita, Japan.
- Division of Hematology/Oncology, Kameda Medical Center, Kamogawa, Japan.
ORCID-Profile: Wataru Kuroki, Akihiro Kitadate, Yuto Takahashi, Takahiro Kobayashi, Sho Ikeda, Kentaro Narita, Kosei Matsue
Förderung
- Japan Society for the Promotion of Science
- Japanese Society of Myeloma Research Award
Zitieren
APA
Kuroki, W., Kitadate, A., Takahashi, Y., Iwama, S., Yamada, M., Kobayashi, T., Ikeda, S., Narita, K., Matsue, K., & Takahashi, N. (2025). Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression. British Journal of Haematology, 206(6), 1615-1626. https://doi.org/10.1111/bjh.20106
Vancouver
Kuroki W, Kitadate A, Takahashi Y, Iwama S, Yamada M, Kobayashi T, et al. Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression. British Journal of Haematology. 2025;206(6):1615-1626. doi:10.1111/bjh.20106
BibTeX
@article{Kuroki2025,
author = {Kuroki, Wataru and Kitadate, Akihiro and Takahashi, Yuto and Iwama, Sayaka and Yamada, Masahiro and Kobayashi, Takahiro and Ikeda, Sho and Narita, Kentaro and Matsue, Kosei and Takahashi, Naoto},
title = {Multiple myeloma with 1q gain/amplification exhibits reduced CD38 expression via interleukin‐6 receptor overexpression},
journal = {British Journal of Haematology},
year = {2025},
volume = {206},
number = {6},
pages = {1615--1626},
doi = {10.1111/bjh.20106}
}
EUVIMED